Comment: impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
Grau
Santiago
S
Mateu-de Antonio
Javier
J
Marin-Casino
Mónica
M
D000081:Acetamides / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000069349:Linezolid; D016106:Methicillin Resistance / Q000187:drug effects / Q000502:physiology; D023303:Oxazolidinones / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D018461:Soft Tissue Infections / Q000188:drug therapy / Q000191:economics*; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000191:economics*; D013211:Staphylococcus aureus / Q000187:drug effects; D016896:Treatment Outcome
D000081:Acetamides; D023303:Oxazolidinones; D000069349:Linezolid